Dynamic Technology Lab Private Ltd Sells 26,654 Shares of Myriad Genetics, Inc. $MYGN

Dynamic Technology Lab Private Ltd lessened its stake in Myriad Genetics, Inc. (NASDAQ:MYGN) by 44.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 33,165 shares of the company’s stock after selling 26,654 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in Myriad Genetics were worth $176,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. CWM LLC boosted its stake in Myriad Genetics by 600.2% in the 1st quarter. CWM LLC now owns 9,796 shares of the company’s stock worth $87,000 after purchasing an additional 8,397 shares during the period. Natixis Advisors LLC raised its holdings in shares of Myriad Genetics by 1.3% during the 1st quarter. Natixis Advisors LLC now owns 212,138 shares of the company’s stock valued at $1,882,000 after buying an additional 2,810 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Myriad Genetics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 10,667,755 shares of the company’s stock worth $94,623,000 after acquiring an additional 76,712 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Myriad Genetics by 3.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,165,395 shares of the company’s stock valued at $10,337,000 after buying an additional 39,860 shares during the period. Finally, Headlands Technologies LLC grew its position in Myriad Genetics by 114.6% during the 1st quarter. Headlands Technologies LLC now owns 46,727 shares of the company’s stock worth $414,000 after acquiring an additional 24,958 shares during the last quarter. Hedge funds and other institutional investors own 99.02% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Piper Sandler lowered their price target on Myriad Genetics from $9.00 to $8.50 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Myriad Genetics in a research note on Monday. TD Cowen upped their price objective on Myriad Genetics from $8.00 to $9.00 and gave the company a “hold” rating in a research report on Tuesday, November 4th. UBS Group lifted their target price on Myriad Genetics from $6.00 to $8.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Finally, Cowen restated a “hold” rating on shares of Myriad Genetics in a research note on Tuesday, November 4th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Myriad Genetics currently has an average rating of “Hold” and a consensus target price of $11.45.

Myriad Genetics Trading Down 3.9%

Shares of MYGN opened at $7.60 on Thursday. The firm has a fifty day simple moving average of $7.48 and a two-hundred day simple moving average of $6.05. The firm has a market cap of $708.43 million, a PE ratio of -1.78 and a beta of 1.99. Myriad Genetics, Inc. has a 1-year low of $3.76 and a 1-year high of $16.83.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, January 16th. The company reported ($0.19) earnings per share (EPS) for the quarter. The firm had revenue of $156.40 million during the quarter. Myriad Genetics had a negative return on equity of 5.17% and a negative net margin of 47.45%. Myriad Genetics has set its FY23 guidance at ($0.33)-($0.28) EPS. As a group, research analysts forecast that Myriad Genetics, Inc. will post -0.3 EPS for the current fiscal year.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.